MedAssets (NAS: MDAS) reported earnings on Feb. 23. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), MedAssets beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share increased.
Margins improved across the board.
MedAssets reported revenue of $156.8 million. The 18 analysts polled by S&P Capital IQ hoped for sales of $151.6 million on the same basis. GAAP reported sales were 47% higher than the prior-year quarter's $106.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.32. The 19 earnings estimates compiled by S&P Capital IQ forecast $0.32 per share on the same basis. GAAP EPS were $0.07 for Q4 versus -$0.87 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 80.1%, 1,150 basis points better than the prior-year quarter. Operating margin was 16.0%, 1,160 basis points better than the prior-year quarter. Net margin was 2.6%, 4,880 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $144.7 million. On the bottom line, the average EPS estimate is $0.21.
Next year's average estimate for revenue is $617.2 million. The average EPS estimate is $1.09.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 59 members out of 70 rating the stock outperform, and 11 members rating it underperform. Among 22 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 19 give MedAssets a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MedAssets is outperform, with an average price target of $15.
The health-care investing landscape is littered with also-rans and a few major winners. Is MedAssets the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
Add MedAssets to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.